Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METABOLIC EFFICIENCY WITH RANOLAZINE FOR LESS ISCHEMIA IN NON-ST ELEVATION ACUTE CORONARY SYNDROMES
2004-001090-25Phase 3Completed
- Sponsor
- CV Therapeutics, Inc.
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non–ST-segment elevation acute coronary syndrome (NSTE-ACS) comparing Ranolazine arm with Placebo arm (2 arms). Started Oct 2004; status: completed.
02
Drugs
ranolazine
03
Conditions
non–ST-segment elevation acute coronary syndrome (NSTE-ACS)
Beyond the preview
Go deeper on 2004-001090-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001090-25.